Crucell launches global brand to reflect and reinforce its leading
position in healthcare innovation
(Thomson Reuters ONE) - Leiden, The Netherlands (November 16, 2009) - Globalbiopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; SwissExchange: CRX) today announced the launch of the global Crucellbrand, a consistent identity for its worldwide activities andproducts. The rebranding is designed to promote recognition of theCrucell name and what it stands for: bringing meaningful innovationto global health, with a focus on combating infectious diseases. Theestablishment of a strong global brand will significantly supportthis mission.Today's launch is a major landmark in Crucell's strategy to build anew global organization out of three companies with a common passionfor healthcare innovation. This ambitious development started in2006, when Crucell-then a Dutch company known for its breakthroughtechnologies-acquired the vaccine companies Berna Biotech ofSwitzerland, SBL Vaccines of Sweden and Berna Products Corporation inthe US. An intensive period of integration has resulted in aresilient and flexible organization geared for optimal performanceand sustainable growth.Crucell's Chief Executive Officer Ronald Brus said:"I am proud to announce the launch of the global Crucell brand, whichreflects and reinforces our position as a world leader in healthcareinnovation. Over the past few years we have worked very hard tointegrate the historically different organizations making up today'sCrucell. We focus on capturing synergies, streamlining operations andbuilding on our common values. Today's announcement is an importantmilestone in this development. We are ready for the next leapforward, as a strongly unified force in the global healthcare arena."Under the global branding program launched today, the use of thebrand names Berna Biotech, SBL Vaccines and Berna ProductsCorporation on product packages, brochures, advertisements and othercommunications will be gradually phased out. All Crucell's marketing,sales and communication materials will be given a consistent look andbranded with the Crucell logo. The eye-shaped logo symbolizesCrucell's vision as a company founded on innovation, continuouslyseeking for solutions to global health threats.The transition to the global Crucell brand will be formalized at thelegal level, resulting in new statutory names for a number of Crucellcompanies. These changes will not have implications for existingcontracts and agreements.About CrucellCrucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharmaceutical company focused on research development,production and marketing of vaccines, proteins and antibodies thatprevent and/or treat infectious diseases. Its vaccines are sold inpublic and private markets worldwide. Crucell's core portfolioincludes a vaccine against hepatitis B, a fully-liquid vaccineagainst five important childhood diseases and a virosome-adjuvantedvaccine against influenza. Crucell also markets travel vaccines, suchas the only oral anti-typhoid vaccine, an oral cholera vaccine andthe only aluminum-free hepatitis A vaccine on the market. The Companyhas a broad development pipeline, with several product candidatesbased on its unique PER.C6® production technology. The Companylicenses its PER.C6® technology and other technologies to thebiopharmaceutical industry. Important partners and licensees includeDSM Biologics, Sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck &Co. Crucell is headquartered in Leiden, the Netherlands, withsubsidiaries in Argentina, China, Italy, Korea, Spain, Sweden,Switzerland, UK and the USA. The Company employs over 1200 people.For more information, please visit www.crucell.com.Forward-looking statementsThis press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certainimportant factors that may cause actual results to differ materiallyfrom those contained in such forward-looking statements. Forinformation relating to these factors please refer to our Form 20-F,as filed with the US Securities and Exchange Commission on April 22,2009, in the section entitled 'Risk Factors'. The Company preparesits financial statements under International Financial ReportingStandards (IFRS).For further information please contact:Crucell N.V.Oya YavuzVice PresidentCorporate Communications & Investor RelationsTel. +31 (0)71 519 7064ir(at)crucell.comwww.crucell.comhttp://hugin.info/132631/R/1355022/328732.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 16.11.2009 - 07:45 Uhr
Sprache: Deutsch
News-ID 8409
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell launches global brand to reflect and reinforce its leading
position in healthcare innovation"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
